Literature DB >> 15278783

Metastatic bone disease: pathogenesis and new strategies for treatment.

Atsumasa Uchida1, Hiroki Wakabayashi, Noritaka Okuyama, Atsushi Okamura, Akihiko Matsumine, Katsuyuki Kusuzaki.   

Abstract

Bone is the third leading site of metastatic disease, after the lung and liver. Pain, pathological fractures, neurological deficits, and forced immobilization significantly decrease the quality of life of patients with bone metastasis. The development of metastasis, from the migration of malignant cells from the primary tumor to their proliferation at a distant site, involves a series of sequential steps: angiogenesis, matrix degradation, cell motility, cell attachment, and cellular proliferation. A better understanding of the pathogenesis of metastasis may be expected to lead to the development of new treatment modalities for bone metastasis. Currently, antiangiogenic agents, matrix metalloproteinase (MMP) inhibitors, and hyperthermia are some of the newer therapeutic modalities that seem to hold promise for the treatment of metastatic bone disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278783     DOI: 10.1007/s00776-004-0788-1

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  4 in total

Review 1.  A novel hyperthermia treatment for bone metastases using magnetic materials.

Authors:  Akihiko Matsumine; Kenji Takegami; Kunihiro Asanuma; Takao Matsubara; Tomoki Nakamura; Atsumasa Uchida; Akihiro Sudo
Journal:  Int J Clin Oncol       Date:  2011-03-04       Impact factor: 3.402

2.  Urologic skeletal metastases: current diagnostic and treatment strategies.

Authors:  Stephanie H Alford; Paul S Chang; Ronald P Williams
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

3.  Novel hyperthermia for metastatic bone tumors with magnetic materials by generating an alternating electromagnetic field.

Authors:  Akihiko Matsumine; Katsuyuki Kusuzaki; Takao Matsubara; Ken Shintani; Haruhiko Satonaka; Toru Wakabayashi; Shinichi Miyazaki; Katsuya Morita; Kenji Takegami; Atsumasa Uchida
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 4.510

4.  Severe toxicity with a generic formulation of zoledronic Acid: a case report.

Authors:  Benito Sanchez
Journal:  Clin Med Insights Case Rep       Date:  2012-10-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.